t
On February 6, 2024, Physiomics plc awarded Dr. Peter Sargent options over 4,064,175 ordinary shares with exercise prices of 1.55p, 2.55p and 3.55p, expiring on February 5, 2034. Following this issue, Dr. Peter Sargent holds options over 4,064,175 ordinary shares, Dr. Christophe Chassagnole holds options over 2,293,543 ordinary shares, and Dr. J Millen holds options over 1,905,454 ordinary shares in Physiomics plc.
| Date | 6 Feb 2024 |
| Time | 07:00:08 |
| Category | Director/PDMR dealings |
| ID | 0885C |
6 February 2024
Physiomics plc
("Physiomics" or the "Company")
Options Award
Physiomics plc (AIM: PYC), announces an award of share options (the "Options") over ordinary shares of 0.4p each in the Company ("Ordinary Shares"). The Company considers that it is important to incentivise its key executives to create shareholder value and, as such, today the Board has approved the award of the following options to Dr Peter Sargent under the Company's existing share option scheme (the "Scheme"):
1. 1,354,725 Options with exercise price of 1.55p, being the greater of (i) the average closing price for the three dealing days immediately preceding the date of grant; and (ii) the closing price on the dealing day immediately prior to the date of grant. Half of these Options vest on award and half six months from the date of award
2. 1,354,725 Options with exercise price of 2.55p, being the exercise price calculated in (1) above plus 1p. One third of these Options vest on each anniversary of the date of award (so none are exercisable immediately, 33.3% from 6 Feb 2025, 66.7% from 6 Feb 2026 and 100% from 6 Feb 2027)
3. 1,354,725 Options with exercise price of 3.55p, being the exercise price calculated in (1) above plus 2p. These Options vest over the same time periods as described under (2) above.
All Options can be exercised within 10 years of the date of grant.
Following this issue, the Directors will hold Options over Ordinary Shares in the Company in accordance with the table below:
|
Option holder |
# Options |
Exercise price(p) |
Date of expiry |
|
|
|
|
|
|
P Sargent |
1,354,725 |
1.55 |
05-Feb-34 |
|
P Sargent |
1,354,725 |
2.55 |
05-Feb-34 |
|
P Sargent |
1,354,725 |
3.55 |
05-Feb-34 |
|
Total P Sargent |
4,064,175 |
|
|
|
|
|
|
|
|
C Chassagnole |
322,615 |
6.17 |
23-Mar-25 |
|
C Chassagnole |
659,641 |
2.50 |
27-Feb-27 |
|
C Chassagnole |
350,000 |
5.35 |
26-Mar-28 |
|
C Chassagnole |
267,000 |
3.16 |
26-Mar-29 |
|
C Chassagnole |
694,287 |
7.55 |
01-Mar-31 |
|
Total C Chassagnole |
2,293,543 |
|
|
|
|
|
|
|
|
J Millen |
520,000 |
5.35 |
26-Mar-28 |
|
J Millen |
400,000 |
3.16 |
26-Mar-29 |
|
J Millen |
985,454 |
7.55 |
01-Mar-31 |
|
Total J Millen |
1,905,454 |
|
|
In addition, Dr Jim Millen is interested in 1,884,393 Ordinary Shares (equivalent to approximately 1.39% of the Company's currently issued share capital); Dr Christophe Chassagnole is interested in 1,102,723 Ordinary Shares (equivalent to approximately 0.81% of the Company's currently issued share capital).
The total number of Ordinary Shares in issue remains unchanged at 135,472,478 Ordinary Shares with voting rights attached (one vote per Ordinary Share). There are no Ordinary Shares held in treasury. This total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Physiomics under the Disclosure and Transparency Rules.
Enquiries:
Physiomics plc
Dr Peter Sargent, CEO
+44 (0)1235 841575
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail in respect of the transaction as described above.
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||||
|
a) |
Name |
Dr Peter Sargent |
|||
|
2 |
Reason for the notification |
||||
|
a) |
Position/status |
CEO |
|||
|
b) |
Initial notification /Amendment |
Initial notification |
|||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
Physiomics PLC (the "Issuer") |
|||
|
b) |
LEI |
213800A71DSZ6ABMTQ91 |
|||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument |
Options over Ordinary Shares |
|||
|
|
|
||||
|
Identification code |
GB00BDR6W943 |
||||
|
|
|
||||
|
b) |
Nature of the transaction |
Issue of options |
|||
|
c) |
Price(s) and volume(s) |
|
|||
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
1.55 pence |
1,354,725 |
|
|
|
|
|
2.55 pence |
1,354,725 |
|
|
|
|
|
3.55 pence |
1,354,725 |
|
|
|
|
|
|
|
|
|
|
d) |
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
4,064,175 ordinary shares |
||||
|
|
|
||||
|
- Price |
Average price of 2.55 pence |
||||
|
|
|
||||
|
e) |
Date of the transaction |
06 February 2024 |
|||
|
f) |
Place of the transaction |
London, AIM |
|||
This announcement is released by Physiomics plc and contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.
Notes to Editor
About Physiomics
Physiomics plc combines cutting edge PKPD and QSP modelling and data science techniques, along with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys.
Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design research across discovery, pre-clinical and clinical studies.
Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.